Evidence map›Paper›PMID 36052317›Full record

ArticleFrontiers in digital health2022

The silent trial - the bridge between bench-to-bedside clinical AI applications.

Jethro C C Kwong, Lauren Erdman, Adree Khondker, Marta Skreta, Anna Goldenberg, Melissa D McCradden, Armando J Lorenzo, Mandy Rickard

Abstract read
In one paragraph

Article in Frontiers in digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Review
  5. AI-based augmentation of oncology clinical trials.Nature reviews. Clinical oncology · 2026
    Review
  6. Article
  7. Reporting of race and ethnicity in studies of artificial intelligence in pediatric urology A secondary analysis of the AI-PEDURO online repository.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Leveraging artificial intelligence for the management of preschool wheeze: A narrative review.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jethro C C KwongDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Lauren ErdmanTemerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, ON, Canada.
Adree KhondkerDivision of Urology, Department of Surgery, The Hospital for Sick Children, Toronto, ON, Canada.
Marta SkretaCentre for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Anna GoldenbergTemerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, ON, Canada.
Melissa D McCraddenTemerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, ON, Canada.
Armando J LorenzoDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Mandy RickardDivision of Urology, Department of Surgery, The Hospital for Sick Children, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As more artificial intelligence (AI) applications are integrated into healthcare, there is an urgent need for standardization and quality-control measures to ensure a safe and successful transition of these novel tools into clinical practice. We describe the role of the silent trial, which evaluates an AI model on prospective patients in real-time, while the end-users (i.e., clinicians) are blinded to predictions such that they do not influence clinical decision-making. We present our experience in evaluating a previously developed AI model to predict obstructive hydronephrosis in infants using the silent trial. Although the initial model performed poorly on the silent trial dataset (AUC 0.90 to 0.50), the model was refined by exploring issues related to dataset drift, bias, feasibility, and stakeholder attitudes. Specifically, we found a shift in distribution of age, laterality of obstructed kidneys, and change in imaging format. After correction of these issues, model performance improved and remained robust across two independent silent trial datasets (AUC 0.85-0.91). Furthermore, a gap in patient knowledge on how the AI model would be used to augment their care was identified. These concerns helped inform the patient-centered design for the user-interface of the final AI model. Overall, the silent trial serves as an essential bridge between initial model development and clinical trials assessment to evaluate the safety, reliability, and feasibility of the AI model in a minimal risk environment. Future clinical AI applications should make efforts to incorporate this important step prior to embarking on a full-scale clinical trial.

Indexed as

artificial intelligencebiasdataset driftfeasibilitystakeholder attitudes

Identifiers

PMID36052317
PMCPMC9424628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.